FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer

Shaylee R. Dave; Thomas A. Samuel; Darko Pucar; Natasha Savage; Hadyn T. Williams

doi:10.1097/RLU.0000000000000553

FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer

Shaylee R. Dave, Thomas A. Samuel, Darko Pucar, Natasha Savage, Hadyn T. Williams

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT.

Original language	English (US)
Pages (from-to)	e63-e67
Journal	Clinical nuclear medicine
Volume	40
Issue number	1
DOIs	https://doi.org/10.1097/RLU.0000000000000553
State	Published - Jan 1 2015

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/RLU.0000000000000553

Cite this

@article{aa133fe0d2804f0b9c8dca151fbf21dc,

title = "FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer",

abstract = "Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT. ",

author = "Dave, {Shaylee R.} and Samuel, {Thomas A.} and Darko Pucar and Natasha Savage and Williams, {Hadyn T.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1097/RLU.0000000000000553",

language = "English (US)",

volume = "40",

pages = "e63--e67",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer

AU - Dave, Shaylee R.

AU - Samuel, Thomas A.

AU - Pucar, Darko

AU - Savage, Natasha

AU - Williams, Hadyn T.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT.

AB - Cutaneous metastases of primary internal malignancies are rare, with an incidence of 0.7% to 10.4%. Cutaneous manifestations due to breast cancer are the most common metastases dermatologists observe, with a prevalence of 2.4% and an incidence of 23.9%. Presence of cutaneous metastases is usually a late event in disease progression, indicating grave prognosis. Recognition of cutaneous breast cancer metastases significantly alters therapeutic plans, especially when the disease was thought to be successfully cured. F-FDG PET CT imaging can detect cutaneous metastasis and sites of distant metastases and monitor response to therapy. We report 3 patients with cutaneous-predominant breast carcinoma seen by FDG PET/CT.

UR - http://www.scopus.com/inward/record.url?scp=85028203886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028203886&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000000553

DO - 10.1097/RLU.0000000000000553

M3 - Article

C2 - 25140546

AN - SCOPUS:85028203886

SN - 0363-9762

VL - 40

SP - e63-e67

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 1

ER -

FDG PET/CT in evaluation of unusual cutaneous manifestations of breast cancer

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this